EICHORCondition: Parkinson Disease · Dyskinesia, Drug-Induced · Dyskinesias · Sponsor: Addex Pharma S.A.
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Patients with Parkinson's Disease on a stable regimen of antiparkinson's medications, including a levodopa preparation administered not less than 3 times daily. * Meet protocol-specified criteria for moderate to severe dyskinesia symptoms based on UDysRS and Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) assessments. * Meet protocol specified criteria for ON time with troublesome dyskinesia based on a standard PD home diary. Exclusion Criteria: * Prior surgical treatment for Parkinson's Disease (e.g., deep brain stimulation). * Other neurological disease (including psychiatric disease and/or cognitive impairment) that, in the opinion of the investigator, would affect the patient's ability to complete study assessments. * Other significant medical condition that may affect the safety of the patient or preclude adequate participation in the study. * Pregnant or breast-feeding. Female patients who are of child-bearing potential must be using adequate contraceptive methods (e.g. oral contraceptive, double-barrier method, intra-uterine device, intra-muscular hormonal contraceptive), and have a negative pregnancy test at Screening. Other protocol-defined inclusion and exclusion criteria may apply
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Xenosciences Inc | Phoenix, Arizona, United States | — |
| Neuro-Pain Medical Center | Fresno, California, United States | — |
| University of California Irvine Medical Center | Irvine, California, United States | — |
| Stanford Neuroscience Health Center | Palo Alto, California, United States | — |
| Pacific Neuroscience Institute | Torrance, California, United States | — |
| Rocky Mountain Movement Disorders Center | Englewood, Colorado, United States | — |
| Chase Family Movement Disorders Center - Vernon | Vernon, Connecticut, United States | — |
| Parkinson's Disease and Movement Disorders Center of Boca Raton Inc | Boca Raton, Florida, United States | — |
| Renstar Medical Research -21 NE 1st Ave | Ocala, Florida, United States | — |
| AES - DRS - Synexus Clinical Research US, Inc. - Orlando | Orlando, Florida, United States | — |
| Neurology Associates of Ormond Beach | Ormond Beach, Florida, United States | — |
| Suncoast Neuroscience Associates Inc | St. Petersburg, Florida, United States | — |
+ 29 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04857359